|
Visual
Field Testing
Description:
Visual field testing is a process to determine defects in the field of
vision and tests
the function of the retina, optic nerve and optic pathways. The process may
include simple
confrontation (not reimbursable) to increasingly complex studies with
sophisticated
equipment.
Indications and
Limitations of Coverage and/or Medical Necessity:
The following diagnoses are covered procedures only for the limited
visual field examination (CPT 92081):
| 374.30 -
374.34 |
Ptosis of
eyelid |
| 374.87 |
Dermatochalasis |
The lowest level of testing
which is medically necessary must be utilized.
Visual field testing is
covered for diagnois and treatment of abnormal signs, symptoms, disease or
injury. Documentation in the record must establish medical necessity for the
service including the frequency of the service.
There must always be a
reason for performing the test since routine exams are not covered or
medically necessary.
CPT/HCPCS Section:
Special opthalmological services
CPT/HCPCS Codes:
| 92081 |
Visual
field examination(s) |
| 92082 |
Visual
field examination(s) |
| 92083 |
Visual
field examination(s) |
ICD-Codes that Support
Medical Necessity:
The use of these ICD-9 codes does not abrogate the requirement that
medical necessity be documented in the patient's record.
| 094.83 -
094.85 |
Syphilitic
retinochoroiditis, optic atrophy, and retrobulbar neuritis |
| 095.0 |
Syphilitic
episcleritis |
| 190.0 -
190.9 |
Malignant
neoplasm of eye |
| 191.0 |
Malignant
neoplasm of cerebrum, except lobes and ventricles |
| 192.0 |
Malignant
neoplasm of cranial nerves |
| 194.3 |
Malignant
neoplasm pituitary gland and craniopharyngeal duct |
| 198.4 |
Secondary
malignant neoplasm, other parts of nervous system |
| 198.89 |
Secondary
malignant neoplasm of other specified sites (04/15/1998) |
| 224.0 -
224.9 |
Benign
neoplasm of eye |
| 225.1 |
Benign
neoplasm of cranial nerves |
| 227.3 |
Benign
neoplasm of pituitary gland and carniopharyngeal duct (pouch)
(04/15/1998) |
| 234.0 |
Carcinoma
in situ of eye |
| 237.0 |
Neoplasm
of uncertain behavior of pituitary gland and rainopharyngeal duct
(04/15/98) |
| 237.70 -
237.9 |
Neoplasm,
uncertain behavior, nervous system |
| 238.8 |
Neoplasm
of uncertain behavior, other specified sites (eye) |
| 239.6 |
Neoplasm
of unspecified nature, brain |
| 239.8 |
Neoplasm
of unspecified nature, other specified sites |
| 242.00 -
242.01 |
Toxic
diffuse goiter |
| 259.8 |
Other
specified endocrine disorders |
| 300.11 |
Conversion
disorder, blindness |
| 346.00 -
346.91 |
Migraine |
| 348.2 |
Benign
intracranial hypertension |
| 360.23 |
Siderosis |
| 360.29 |
Other
degenerative disorders of globe |
| 361.10 -
361.12 |
Retinoschisis |
| 362.01 -
362.9 |
Other
retinal disorders |
| 363.10 -
363.15 |
Disseminated
chorioretinitis and desseminated retinochoroiditis (12/04/1997) |
| 363.20 -
363.22 |
Other and
unspecified forms of chorioretinitis and retinochoroiditis
(12/04/1997) |
| 363.30 -
363.35 |
Chorioretinal
scars (12/04/1997) |
| 363.40 -
363.43 |
Choroidal
degenerations (12/04/1997) |
| 363.50 -
363.57 |
Hereditary
choroidal dystrophies (12/04/1997) |
| 363.61 -
363.63 |
Choroidal
hemorrhage and rupture (12/04/1997) |
| 363.70 -
363.72 |
Choroidal
detachment (12/04/1967) |
| 363.8 |
Other
disorders of choroid (12/04/1997) |
| 363.9 |
Unspecified
disorder of choroid (12/04/1997) |
| 365.00 -
365.9 |
Glaucoma |
| 368.00 -
368.9 |
Visual
disturbances |
| 369.00 -
369.9 |
Profound
impairment, both eyes |
| 374.30 -
374.34 |
Ptosis of
eyelid (payable only for CPT 92081) (12/04/1997) |
| 374.87 |
Dermatochalasis
(payable only for CPT 92081) (12/04/1997) |
| 376.00 -
376.9 |
Disorders
of the orbit |
| 377.00 -
377.9 |
Disorders
of the optic nerve and visual pathways |
| 378.55 |
External
ophthalmoplegia |
| 437.3 |
Cerebral
aneurysm, nonruptured (12/97) |
| 446.5 |
Giant
cell arteritis (12/29/1997) |
| 743.20 -
743.22 |
Buphthalmos |
| 743.44 |
Specified
anomalies of anterior chamber, chamber angle, and related structures |
| 743.52 -
743.53 |
Fundus
coloboma to chorioretinal degeneration, congenital |
| 743.55 -
743.59 |
Congenital
macular changes to other congenital anomalies of posterior segment |
| 743.61 |
Congenital
ptosis |
| 950.0 -
950.9 |
Optic
nerve injury to unspecified injury to optic nerve and pathways |
| 995.2 |
Unspecified
adverse effect of drug, medicinal and biological substance |
| V45.61 -
V45.69 |
Postsurgical
states following surgery of eye and adnexa (07/20/98) |
| V58.63 |
Long-term
(current) use of antiplatelets/antithrombotics (Added 10/01/2003) |
| V58.64 |
Long-term
(current) use of non-steroidal anti-inflammatories (NSAID)(Added
10/01/2003) |
| V58.65 |
Long-term
(current) use of steroids (added 10/01/2003) |
| V58.69 |
Long term
(current) use of other (high-risk) medications (12/97) |
| V58.83 |
Encounter
for therapeutic drug monitoring (09/19/2000) |
| V65.2 |
Person
feigning illness |
| V80.2 |
Special
screening for other eye conditions |
Reasons for Denials:
Lack of medical necessity. Screening examination.
Non-covered ICD-9 Codes:
All other diagnosis codes, which are not listed as covered in the
"ICD-9-CM Codes that Support Medical Necessity" section of this
policy.
Coding Guidelines:
All services are considered bilateral. Modifier 50 is not appropriate.
The beneficiary is not
liable for services denied as not reasonable or necessary unless a waiver
has been signed. When this has been completed, the GA modifier should be
used.
If the service is performed
in a hospital inpatient or outpatient setting, the modifier 26 should be
used to indicate the professional component.
If the visual field
examination is medically necessary following laser therapy, the appropriate
ICD-9 code should be billed as diagnosis #1 and V45.6 (status following
surgery of eye and adnexa) should be billed as diagnosis #2.
Documentation
Requirements:
For EMC users: when submitting a claim requires supporting documentation,
this information can be included in the appropriate "narrative"
record for your claim submission format.
When two or more
examinations are performed per year per beneficiary, documentation
indicating the medical necessity for the procedure must be submitted with
the claim.
|